Faculty member in the Division of Infectious Diseases with a secondary appointment in the Department of Epidemiology, Rollins School of Public Health, Emory University
Principal investigator on the PURPOSE 2 trial
Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH
June 20th 2025The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.